Wilmington Savings Fund Society FSB Cuts Stake in Zoetis Inc. $ZTS

Key Points

• Wilmington Savings Fund Society FSB has reduced its stake in Zoetis Inc. by 4.2%, now holding 41,484 shares valued at approximately $6.47 million.
• Zoetis reported impressive quarterly earnings of $1.76 per share, exceeding estimates, and a quarterly revenue of $2.46 billion, a 4.2% increase year-over-year.
• The company recently declared a quarterly dividend of $0.50, anticipated to yield 1.4%, payable on December 2nd to investors of record.

Wilmington Savings Fund Society FSB decreased its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 4.2% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 41,484 shares of the company's stock after selling 1,838 shares during the period. Wilmington Savings Fund Society FSB's holdings in Zoetis were worth $6,469,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in ZTS. Brighton Jones LLC boosted its stake in shares of Zoetis by 180.4% in the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company's stock valued at $754,000 after purchasing an additional 2,978 shares in the last quarter. Dynamic Advisor Solutions LLC bought a new stake in Zoetis during the 1st quarter valued at $1,253,000. Sound Income Strategies LLC raised its holdings in Zoetis by 141.4% during the 1st quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock valued at $46,000 after buying an additional 164 shares during the last quarter. Exchange Traded Concepts LLC raised its holdings in Zoetis by 6.8% during the 1st quarter. Exchange Traded Concepts LLC now owns 7,909 shares of the company's stock valued at $1,302,000 after buying an additional 505 shares during the last quarter. Finally, Cyndeo Wealth Partners LLC bought a new stake in Zoetis during the 1st quarter valued at $206,000. Hedge funds and other institutional investors own 92.80% of the company's stock.

Zoetis Stock Up 0.8%

Shares of NYSE ZTS opened at $143.45 on Wednesday. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a 12 month low of $139.34 and a 12 month high of $196.55. The firm has a market capitalization of $63.58 billion, a PE ratio of 24.69, a price-to-earnings-growth ratio of 2.28 and a beta of 0.90. The firm has a fifty day simple moving average of $148.98 and a two-hundred day simple moving average of $154.11.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.14. The company had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. Zoetis's quarterly revenue was up 4.2% compared to the same quarter last year. During the same period last year, the business earned $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be paid a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 1.4%. The ex-dividend date is Friday, October 31st. Zoetis's dividend payout ratio (DPR) is presently 34.42%.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on ZTS shares. Leerink Partners lowered shares of Zoetis from an "outperform" rating to a "market perform" rating and lowered their price target for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Leerink Partnrs lowered shares of Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. Stifel Nicolaus lowered shares of Zoetis from a "buy" rating to a "hold" rating and lowered their price target for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Weiss Ratings restated a "hold (c-)" rating on shares of Zoetis in a report on Wednesday, October 8th. Finally, Piper Sandler upped their price objective on shares of Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a report on Monday, August 11th. Four analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $196.71.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.